SVB Wealth’s Pacific Biosciences PACB Stock Holding History

SVB Wealth’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-19,000	Closed	-$115K	–	522
2019 Q2	$115K	Buy	+19,000	New	+$133K	﹤0.01%	507

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Versor Investments New York $47.5M AUM 100.43% 1-Year Est. Return

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Water Island Capital New York $1.08B AUM 105.75% 1-Year Est. Return

Kite Lake Capital Management (UK) London, United Kingdom $290M AUM 183.72% 1-Year Est. Return

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

SVB Wealth's PACB Position: Q3 2019 in Review

SVB Wealth sold out of Pacific Biosciences (PACB) in Q3 2019, closing a stake of 19,000 shares — an estimated $115K sold.

SVB Wealth first reported a position in PACB in Q2 2019 and held it in 1 quarter. The position peaked at $115K in Q2 2019. 148 funds tracked by Wall St. Rank hold PACB as of Q3 2019.

SVB Wealth reported no remaining Pacific Biosciences position as of Q3 2019 after selling out during the quarter.
SVB Wealth sold 19,000 Pacific Biosciences shares in Q3 2019, an estimated $115K.
SVB Wealth first reported a position in Pacific Biosciences in Q2 2019 and held it in 1 quarter.
SVB Wealth's Pacific Biosciences position peaked at $115K in Q2 2019.
148 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2019.

Based on SVB Wealth's 13F filing for Q3 2019, filed 1 Nov 2019.